Q-omics provides the consensus-scored WFDC9 profile across patient tissues and cancer cell-line models. WFDC9 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, WFDC9 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, WFDC9 RNA expression shows 4,834 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight UCEC, and COAD as cancer lineages where WFDC9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC9 survival associations across molecular data types. WFDC9 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC9 RNA expression–survival associations across cancer types. High WFDC9 expression shows unfavorable associations in UCEC, MESO, BLCA, OV, LUSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for WFDC9 RNA expression.
This table summarizes WFDC9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC9 shows lower tumor expression in PRAD and higher tumor expression in COAD. The COAD box plot shows higher WFDC9 RNA expression in tumor versus normal tissue (log2 FC = +0.151, t-test p < 0.001).
This table shows molecular features associated with WFDC9 in patient tissues and cancer cell lines. In patient samples, WFDC9 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
